These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 28276313

  • 1. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
    Tan W, Zhu S, Cao J, Zhang L, Li W, Liu K, Zhong J, Shang C, Chen Y.
    Oncol Res; 2017 Nov 02; 25(9):1543-1553. PubMed ID: 28276313
    [Abstract] [Full Text] [Related]

  • 2. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF, Gao ZH, Qu XJ.
    Oncotarget; 2016 Jun 14; 7(24):36767-36782. PubMed ID: 27167344
    [Abstract] [Full Text] [Related]

  • 3. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 14; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 4. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M, Fei Z, Zhang G.
    Biomed Pharmacother; 2018 Jan 14; 97():1282-1288. PubMed ID: 29156516
    [Abstract] [Full Text] [Related]

  • 5. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.
    Anticancer Res; 2010 Dec 14; 30(12):4951-8. PubMed ID: 21187475
    [Abstract] [Full Text] [Related]

  • 6. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J, Zhai B, Sun W, Hu F, Cheng H, Xu J.
    PLoS One; 2017 Dec 14; 12(9):e0185088. PubMed ID: 28934275
    [Abstract] [Full Text] [Related]

  • 7. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 8. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM.
    J Surg Res; 2012 Aug 06; 176(2):542-8. PubMed ID: 22261591
    [Abstract] [Full Text] [Related]

  • 9. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, Daily MF, Shah M, Evers BM.
    Anticancer Res; 2012 Jul 06; 32(7):2531-6. PubMed ID: 22753710
    [Abstract] [Full Text] [Related]

  • 10. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H, Zhang C, Chi H, Meng Z.
    Int J Oncol; 2018 Jun 06; 52(6):2051-2060. PubMed ID: 29620259
    [Abstract] [Full Text] [Related]

  • 11. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M, Chen C, Geng J, Han D, Wang T, Xie T, Wang L, Wang Y, Wang C, Lei Z, Chu X.
    Cancer Lett; 2017 Jul 10; 398():12-21. PubMed ID: 28377178
    [Abstract] [Full Text] [Related]

  • 12. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
    Dai N, Ye R, He Q, Guo P, Chen H, Zhang Q.
    Oncol Rep; 2018 Dec 10; 40(6):3235-3248. PubMed ID: 30272354
    [Abstract] [Full Text] [Related]

  • 13. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT, Liu YC, Chiang IT, Liu RS, Wang HE, Lin WJ, Hwang JJ.
    Int J Oncol; 2014 Jul 10; 45(1):177-88. PubMed ID: 24807012
    [Abstract] [Full Text] [Related]

  • 14. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
    Zhang QB, Sun HC, Zhang KZ, Jia QA, Bu Y, Wang M, Chai ZT, Zhang QB, Wang WQ, Kong LQ, Zhu XD, Lu L, Wu WZ, Wang L, Tang ZY.
    PLoS One; 2013 Jul 10; 8(2):e55945. PubMed ID: 23409093
    [Abstract] [Full Text] [Related]

  • 15. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
    Ha TY, Hwang S, Moon KM, Won YJ, Song GW, Kim N, Tak E, Ryoo BY, Hong HN.
    Anticancer Res; 2015 Apr 10; 35(4):1967-76. PubMed ID: 25862849
    [Abstract] [Full Text] [Related]

  • 16. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
    Gedaly R, Galuppo R, Musgrave Y, Angulo P, Hundley J, Shah M, Daily MF, Chen C, Cohen DA, Spear BT, Evers BM.
    J Surg Res; 2013 Nov 10; 185(1):225-30. PubMed ID: 23769634
    [Abstract] [Full Text] [Related]

  • 17. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W, Song T, Li Q, Zhu X, Yin H, Sun H, Zhang T.
    J Hematol Oncol; 2016 Mar 08; 9():20. PubMed ID: 26957312
    [Abstract] [Full Text] [Related]

  • 18. Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma In Vivo.
    Tsai JJ, Hsu FT, Pan PJ, Chen CW, Kuo YC.
    Anticancer Res; 2018 Apr 08; 38(4):2119-2125. PubMed ID: 29599330
    [Abstract] [Full Text] [Related]

  • 19. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M, de Gramont A, Tijeras-Raballand A, Dos Santos C, Riveiro ME, Slimane K, Faivre S, Raymond E.
    Cancer Chemother Pharmacol; 2013 May 08; 71(5):1297-307. PubMed ID: 23479136
    [Abstract] [Full Text] [Related]

  • 20. Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma.
    Liang Y, Chen J, Yu Q, Ji T, Zhang B, Xu J, Dai Y, Xie Y, Lin H, Liang X, Cai X.
    Cancer Med; 2017 Dec 08; 6(12):2787-2795. PubMed ID: 29030911
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.